News about Clinical Trials

VectorY Doses First Patient in Phase I/II PIONEER-ALS Trial of TDP-43 Targeting Therapy VTx-002

VectorY initiates clinical evaluation of VTx-002, a first-in-class vectorised antibody therapy targeting TDP-43 pathology in ALS, with first patient dosed at Mass General Brigham.

Clinical Trials | 11/02/2026 | By News Bureau

Roche's Fenebrutinib Matches Ocrevus in Slowing Disability Progression in PPMS Phase III Trial

Phase III FENtrepid study shows oral BTK inhibitor fenebrutinib achieved non-inferiority to Ocrevus in primary progressive multiple sclerosis, reducing disability progression risk by 12 percent with consistent subgroup benefit.

Clinical Trials | 10/02/2026 | By News Bureau

Late-breaking Data Highlight Positive Safety and Closure Rates for Abbott's New Stroke-prevention Device in non-Valvular AFib

Abbott has reported positive late-breaking data from the VERITAS Study showing its Amulet 360 Left Atrial Appendage Occluder met safety and effectiveness endpoints, supporting its potential to reduce stroke risk in patients with non-valvular atrial fibrillation.

Clinical Trials | 09/02/2026 | By News Bureau

Delonix Bioworks Secures NMPA IND Clearance for MenB Vaccine Candidate DX-104

China grants IND approval for DX-104 after Australia CTN clearance, paving the way for Phase I trials of Delonix’s engineered Group B meningococcal vaccine.

Clinical Trials | 09/02/2026 | By News Bureau

Roche's Fenebrutinib Becomes First Investigational Therapy in Over a Decade to Slow Disability Progression in PPMS

Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.

Clinical Trials | 09/02/2026 | By News Bureau

Alvotech Announces Positive Results from Pharmacokinetic Study for Entyvio

Alvotech has reported positive top-line results from a pivotal pharmacokinetic study of AVT80, its proposed biosimilar to Entyvio. The study met all primary endpoints, demonstrating comparable pharmacokinetics, safety, tolerability and immunogenicity to the reference product in healthy adult participants.

Clinical Trials | 06/02/2026 | By News Bureau

Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss

Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.

Clinical Trials | 04/02/2026 | By News Bureau |  104

Avobis Bio to Present Expanded STOMP2 Trial Data on AVB-114 at ECCO Congress

Expanded STOMP2 trial data highlight sustained safety and efficacy of AVB-114, as Avobis Bio prepares for Phase III development in Crohn’s disease.

Clinical Trials | 30/01/2026 | By News Bureau

SK Bioscience Begins Study of Sarbecovirus Vaccine

SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.

Clinical Trials | 30/01/2026 | By News Bureau

Boehringer Ingelheim's Apecotrep Cuts Proteinuria by 40 percent in Phase II Trial for Rare Kidney Disease FSGS

Phase II data show apecotrep, a first-in-class oral TRPC6 inhibitor, significantly reduced proteinuria in patients with primary FSGS, supporting ongoing Phase III development.

Clinical Trials | 29/01/2026 | By News Bureau